Roche and Flatiron Unveil Cross-Border Oncology Data Study at ISPOR Europe 2025
Roche Holding AG, in collaboration with Flatiron Health and Pfizer, has announced the presentation of new research at the upcoming ISPOR Europe 2025 Conference, scheduled for November 9-12 in Glasgow, Scotland, UK. The research includes a Top 5% Award Poster assessing the transportability of survival outcomes between the US and Austria, highlighting the challenges of applying real-world evidence across different healthcare settings. Results from this and other studies will be presented at the conference. In total, Flatiron's real-world data will be featured in more than 18 research presentations, including two Top 5% Award acceptances and ten other Flatiron-authored abstracts.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023007694) on October 23, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。